---
title: "STOCKS | DubaHits 52-Week High; Innovent Falls 4.84%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297454635.md"
description: "Two listed companies recorded unusual trading moves at 10:21 am, according to ETNet. Dubarose 45.07% to HK$0.515, hitting a 52-week high. The stock has gained for two straight sessions and is up 66.13% over that period. Innovent Biologicsfell 4.84% to HK$102.30, extending its decline to three sessions for a cumulative drop of 6.83%."
datetime: "2026-08-31T02:27:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297454635.md)
  - [en](https://longbridge.com/en/news/297454635.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297454635.md)
generator: "portal-rs"
---

# STOCKS | DubaHits 52-Week High; Innovent Falls 4.84%

Two listed companies recorded unusual trading moves at 10:21 am, according to ETNet. Duba (01753) rose 45.07% to HK$0.515, hitting a 52-week high. The stock has gained for two straight sessions and is up 66.13% over that period. Innovent Biologics (01801) fell 4.84% to HK$102.30, extending its decline to three sessions for a cumulative drop of 6.83%.

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [01753.HK](https://longbridge.com/en/quote/01753.HK.md)

## Related News & Research

- [Innovent Biologics files HKEX next-day disclosure return, issues 182,021 new shares](https://longbridge.com/en/news/297204810.md)
- [Innovent Biologics: 2026H1 revenue and profit soared, driven by robust product growth and global expansion](https://longbridge.com/en/news/296925554.md)
- [Innovent Biologics reports 1H results](https://longbridge.com/en/news/296950734.md)
- [Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118](https://longbridge.com/en/news/297573070.md)
- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**